ScreenerHero

CRON Cronos Group Inc.

NAS · US · Healthcare · Drug Manufacturers - Specialty & Generic · thecronosgroup.com
3.285USD+1.08%Mkt Cap: 1.21B $P/E: 17.29

Cronos Group Inc., a cannabinoid company, engages in the cultivation, production, distribution, and marketing of cannabis products in Canada, Israel, and internationally. It offers dried flowers, pre-rolls, oils, vaporiz…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
Merck KGaA
$65.69BUSDP/E 25.5
TAK
Takeda Pharmaceutical Company Limited
$57.82BUSD
TEVA
Teva Pharmaceutical Industries Limited
$45.64BUSDP/E 65.2
HLN
Haleon plc
$39.01BUSDP/E 18.1
ZOE
Zoetis Inc.
$28.56BUSDP/E 12.2
ZTS
Zoetis Inc.
$29.48BUSDP/E 11.7
UTHR
United Therapeutics Corporation
$23.23BUSDP/E 19.4
VTRS
Viatris Inc.
$20.15BUSD
SOBI
Swedish Orphan Biovitrum AB (publ)
$14.27BUSDP/E 111.6
NBIX
Neurocrine Biosciences, Inc.
$14.79BUSDP/E 21.3
IPN
Ipsen S.A.
$12.60BUSDP/E 22.8
ELAN
Elanco Animal Health Incorporated
$11.23BUSD
RDY
Dr. Reddy's Laboratories Limited
$10.40BUSDP/E 28.4
KRK
Krka, d. d.
$8.63BUSDP/E 19.3
AMRX
Amneal Pharmaceuticals, Inc.
$7.07BUSDP/E 41.4
ALKS
Alkermes plc
$6.99BUSDP/E 109.6
HIMS
Hims & Hers Health, Inc.
$6.88BUSD
LNTH
Lantheus Holdings, Inc.
$6.53BUSDP/E 24.2
KNSA
Kiniksa Pharmaceuticals International, plc
$5.93BUSDP/E 77.9
APTX
Apotex Health Corp.
$5.27BUSD

Key Statistics

Company
Market Cap1.21B USD
Enterprise Value463.29M USD
Revenue (TTM)179.09M USD
Gross Profit62.76M USD
Net Income (TTM)-9.45M USD
Revenue/Share0.47 USD
Last Price3.285 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees610
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)17.29
P/E (Forward)-82.13
PEG—
EV/EBITDA39.00
EV/Revenue2.59
P/S6.76
P/B1.14
EPS (TTM)0.19
EPS (Forward)-0.04
52W Range
2.28077% of range3.580
52W High3.580 USD
52W Low2.280 USD
Profitability
Gross Margin42.81%
Oper. Margin15.44%
EBITDA Margin6.63%
Profit Margin-6.44%
ROE-0.86%
ROA-0.79%
Growth
Revenue Growth58.40%
Earnings Growth—
Cash Flow & Leverage
Operating CF25.87M USD
CapEx (TTM)26.06M USD
FCF Margin3.41%
FCF Yield0.50%
Net Debt-795.72M USD
Net Debt/EBITDA-66.99
Balance Sheet
Debt/Equity0.00
Current Ratio16.18
Quick Ratio15.15
Book Value/Sh2.88 USD
Cash/Share2.16 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.5 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)2.466 USD
Upside (mean)-24.9%
Target Range2.466 USD – 2.466 USD
# Analysts1
Ownership
Shares Out.368.41M
Float186.99M
Insiders49.14%
Institutions15.51%
Short Interest
Short Ratio2.8d
Short % Float1.78%
Short % Out.0.88%
Shares Short3.25M
Short (prev mo.)3.38M
Technical
SMA 503.200 (+2.7%)
SMA 2002.801 (+17.3%)
Beta1.20
S&P 52W Chg16.45%
Avg Vol (30d)1.01M
Avg Vol (10d)1.04M
Technical Indicators
RSI (14)52.1
MACD0.0299
MACD Signal0.0499
MACD Hist.-0.0201
BB Upper3.458 USD
BB Middle3.278 USD
BB Lower3.099 USD
BB Width10.95%
ATR (14)0.1038 USD
Vol Ratio (20d)0.74x